Autocrine-derived Epidermal Growth Factor Receptor Ligands Contribute to Recruitment of Tumor-associated Macrophage and Growth of Basal Breast Cancer Cells in Vivo

Overview

Journal Oncol Res

Specialty Oncology

Date 2013 Jul 25

PMID 23879171

Citations 12

Authors

Nicole K Nickerson

Christopher P Mill

Hsin-Jung Wu

David J Riese 2nd

John Foley

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor (EGFR) expression has been linked to progression of basal breast cancers. Many breast cancer cells harbor the EGFR and produce its family of ligands, suggesting they may participate in autocrine and paracrine signaling with cells of the tumor microenvironment. EGFR ligand expression was profiled in the basal breast cancer cell line MDA-231 where AREG, TGF-alpha, and HBEGF were the three ligands most highly expressed. Autocrine signaling was modulated through silencing or overexpression of these three ligands using lentiviral constructs and the impact measured using motility, proliferation, and cytokine expression assays. Changes in receptor phosphorylation and receptor turnover were examined. Knockdown of AREG or TGF-alpha in vitro resulted in decreased motility (p < 0.05) and decreased expression of macrophage chemoattractants. Overexpression of TGF-alpha increased motility and chemoattractant expression, whereas AREG did not. HBEGF modulation had no effect on any cellular behaviors. All the cells with altered ligand production were inoculated into female athymic nude mice to form mammary fat pad tumors, followed by immunohistochemical analysis for necrosis, angiogenesis, and macrophage recruitment. In vivo, knockdown of AREG or TGF-alpha increased survival (p < 0.001) while decreasing angiogenesis (p < 0.001), tumor growth (p < 0.001), and macrophage attraction (p < 0.001). Overexpression of AREG appeared to elicit a greater effect than TGF-alpha on mammary fat pad tumor growth by increasing angiogenesis (p < 0.001) and macrophage attraction to the tumor (p < 0.01). We propose these changes in mammary tumor growth were the result of increased recruitment of macrophages to the tumor by cells with altered autocrine EGFR signaling. We conclude that AREG and TGF-alpha were somewhat interchangeable in their effects on EGFR signaling; however, TGF-alpha had a greater effect in vitro and AREG had a greater effect in vivo.

Citing Articles

Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy.

Li P, Kong X, He Y, Liu Y, Peng X, Li Z Mil Med Res. 2022; 9(1):52.

PMID: 36154923 PMC: 9511789. DOI: 10.1186/s40779-022-00414-y.

Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis.

Kemmer S, Berdiel-Acer M, Reinz E, Sonntag J, Tarade N, Bernhardt S Cancers (Basel). 2022; 14(10).

PMID: 35625984 PMC: 9139462. DOI: 10.3390/cancers14102379.

Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.

Gangapuram M, Mazzio E, Redda K, Soliman K Int J Mol Sci. 2021; 22(14).

PMID: 34299315 PMC: 8306781. DOI: 10.3390/ijms22147694.

Single-cell RNA-seq dissects the intratumoral heterogeneity of triple-negative breast cancer based on gene regulatory networks.

Zhou S, Huang Y, Liu H, Zhou X, Yuan M, Hou F Mol Ther Nucleic Acids. 2021; 23:682-690.

PMID: 33575114 PMC: 7851423. DOI: 10.1016/j.omtn.2020.12.018.

Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment.

Sasidharan Nair V, Saleh R, Toor S, Cyprian F, Elkord E Cancer Immunol Immunother. 2021; 70(8):2103-2121.

PMID: 33532902 PMC: 8289790. DOI: 10.1007/s00262-020-02842-y.

References

Nickerson N, Mohammad K, Gilmore J, Crismore E, Bruzzaniti A, Guise T . Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One. 2012; 7(1):e30255. PMC: 3261896. DOI: 10.1371/journal.pone.0030255. View

Wu W, Tse T, Sung J, Li Z, Yu L, Cho C . Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res. 2009; 29(1):229-34. View

Price J, Tiganis T, Agarwal A, Djakiew D, Thompson E . Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. Cancer Res. 1999; 59(21):5475-8. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

Willmarth N, Baillo A, Dziubinski M, Wilson K, Riese 2nd D, Ethier S . Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal. 2008; 21(2):212-9. PMC: 2632975. DOI: 10.1016/j.cellsig.2008.10.003. View

Shoyab M, Plowman G, McDonald V, BRADLEY J, Todaro G . Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science. 1989; 243(4894 Pt 1):1074-6. DOI: 10.1126/science.2466334. View

Leek R, Harris A . Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002; 7(2):177-89. DOI: 10.1023/a:1020304003704. View

Higashiyama S, Abraham J, Miller J, Fiddes J, Klagsbrun M . A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991; 251(4996):936-9. DOI: 10.1126/science.1840698. View

Hirsch D, Shen Y, Wu W . Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res. 2006; 66(7):3523-30. DOI: 10.1158/0008-5472.CAN-05-1547. View

10.

Voloshin T, Gingis-Velitski S, Bril R, Benayoun L, Munster M, Milsom C . G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood. 2011; 118(12):3426-35. PMC: 3179406. DOI: 10.1182/blood-2010-11-320812. View

11.

Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T . Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem. 1995; 270(13):7495-500. DOI: 10.1074/jbc.270.13.7495. View

12.

Davidson N, Gelmann E, Lippman M, Dickson R . Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol. 1987; 1(3):216-23. DOI: 10.1210/mend-1-3-216. View

13.

Wilhelm S, Collier I, Marmer B, Eisen A, Grant G, Goldberg G . SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 1989; 264(29):17213-21. View

14.

Riese 2nd D, Bermingham Y, van Raaij T, Buckley S, Plowman G, Stern D . Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene. 1996; 12(2):345-53. View

15.

Mizutani K, Sud S, McGregor N, Martinovski G, Rice B, Craig M . The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia. 2009; 11(11):1235-42. PMC: 2767225. DOI: 10.1593/neo.09988. View

16.

Cataisson C, Lieberherr M, Cros M, Gauville C, Graulet A, Cotton J . Parathyroid hormone-related peptide stimulates proliferation of highly tumorigenic human SV40-immortalized breast epithelial cells. J Bone Miner Res. 2000; 15(11):2129-39. DOI: 10.1359/jbmr.2000.15.11.2129. View

17.

Kochupurakkal B, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G . Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem. 2004; 280(9):8503-12. DOI: 10.1074/jbc.M413919200. View

18.

Konstantinopoulos P, Vandoros G, Karamouzis M, Gkermpesi M, Sotiropoulou-Bonikou G, Papavassiliou A . EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF. Cell Oncol. 2007; 29(6):477-82. PMC: 4618411. DOI: 10.1155/2007/831416. View

19.

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View

20.

Kenny P, Bissell M . Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest. 2007; 117(2):337-45. PMC: 1764856. DOI: 10.1172/JCI29518. View